RIGL Stock Surges 41.4% in a Year: Time to Buy or Sell?

Shares of biotechnology company Rigel Pharmaceuticals, Inc. (RIGL) have surged 41.4% in the past year against the industry’s decline of 13.4%. The stock also outperformed the sector and S&P 500 Index during this time frame.The outperformance can be attributed to the strong growth of leading drug, Tavalisse, and an impressive pipeline progress.RIGL Outperforms Industry, Sector and IndustryImage Source: Zacks Investment ResearchTavalisse Growth Boosts RIGL’s Top LineRigel’s first approved product Tavalisse (f ...